BiG Research Flash Note: Pfizer
Pfizer produces pharmaceuticals divided mainly by the segments of internal medicine
(18% of revenues), vaccines (11%), oncology (11%), inflammation & immunology (7.5%),
rare diseases (4%) and consumer healthcare (7%). Legacy established products which
include Lipitor (cardiovascular treatment), EpiPen (treat anaphylaxis), Zithromax
(antibiotic) and Xanax (tranquilizer) represent 21% of total revenues.
In geographical terms, Pfizer is mainly present in US (49% of sales), while Developed
Europe represents only 16% of sales, Emerging Markets 22% and the rest of the world
13%.
Pfizer is a research-based biopharmaceutical company. The company is engaged in discovering, developing, manufacturing and distributing of healthcare products, including medicines and vaccines. The company manages its commercial operations through three businesses: Pfizer Biopharmaceuticals Group, which includes Oncology, Inflammation and Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine business units, as well as a hospital business unit; Upjohn, which includes the company's solid oral dose brands such as Lyrica, Lipitor, Norvasc, Celebrex, Viagra, and certain generic medicines; and Consumer Healthcare, which is an over-the-counter medicines business.
Banco de Investimento Global, S.A. (BiG) is a privately-held, specialized financial institution, with headquarters in Lisbon, and is licensed to operate in all business areas open to the banking sector in Portugal.
BiG Research specializes in finding long term investment ideas in European and US markets.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.